× You have changed the size of your browser. Reload the page for best representation and functionality.
Reload
× For horizontal scrolling please use the arrows.
OK
Print table
Last update 28/04/2016 / This consensus includes the transaction between Sanofi and Boehringer Ingelheim.
Business P&L (in EURm except otherwise stated)Q1 2015FY 2015Q1 2016EFY 2016EFY 2017EFY 2018EFY 2019EFY 2020E
Net sales
- Number of Estimates     17 21 
- Highest     9,019 38,345 38,869 41,078 42,591 44,672 
- Consensus 8,810 37,057 8,730 37,227 37,274 39,113 41,115 43,112 
- Lowest     8,487 36,377 35,815 37,212 39,158 40,718 
Other revenues
- Number of Estimates     14 15 
- Highest     100 371 318 318 318 318 
- Consensus 80 360 78 313 270 254 241 234 
- Lowest     59 232 221 131 81 61 
Cost of sales
- Number of Estimates     14 15 
- Highest     -2,711 -11,533 -11,329 -11,573 -12,337 -12,824 
- Consensus -2,786 -11,804 -2,807 -11,931 -11,993 -12,481 -13,013 -13,545 
- Lowest     -2,910 -12,543 -12,974 -13,441 -14,109 -14,818 
Gross Profit
- Number of Estimates     14 15 
- Highest     6,186 26,495 27,780 28,772 30,494 31,973 
- Consensus 6,104 25,613 5,997 25,553 25,552 26,886 28,344 29,802 
- Lowest     5,809 24,994 24,030 25,214 26,945 28,082 
Gross margin as % of net sales
- Number of Estimates     14 14 
- Highest     69.3 69.3 71.5 71.7 71.6 71.6 
- Consensus 69.3 69.1 68.7 68.7 68.5 68.7 68.9 69.1 
- Lowest     67.8 67.7 67.0 66.9 66.8 66.9 
R&D expenses
- Number of Estimates     15 16 
- Highest     -1,252 -5,315 -5,356 -5,523 -5,695 -5,872 
- Consensus -1,199 -5,259 -1,313 -5,510 -5,633 -5,825 -6,013 -6,215 
- Lowest     -1,367 -5,662 -5,895 -6,089 -6,332 -6,609 
SG&A expenses
- Number of Estimates     15 16 
- Highest     -2,420 -10,042 -9,827 -10,204 -10,503 -10,747 
- Consensus -2,438 -10,247 -2,531 -10,418 -10,301 -10,672 -11,042 -11,372 
- Lowest     -2,615 -10,800 -10,822 -11,275 -11,795 -12,419 
Other current operating income/expense
- Number of Estimates     14 14 
- Highest     253 418 50 50 50 50 
- Consensus -67 -203 154 76 -44 -231 -469 -724 
- Lowest     -47 -195 -256 -411 -875 -1,451 
Share of profit/loss of associates
- Number of Estimates     15 14 
- Highest     64 291 397 534 611 714 
- Consensus 31 170 48 237 325 356 352 394 
- Lowest     30 126 195 68 -376 -660 
Net income attributable to non-controlling interests
- Number of Estimates     14 14 
- Highest     -19 -80 -81 -65 -8 -9 
- Consensus -33 -126 -35 -112 -102 -97 -77 -75 
- Lowest     -125 -156 -140 -150 -160 -170 
Business operating income
- Number of Estimates     17 20 
- Highest     2,483 10,257 10,426 11,593 11,634 12,961 
- Consensus 2,398 9,948 2,330 9,822 9,636 10,260 10,926 11,631 
- Lowest     2,125 9,404 8,699 9,272 10,182 10,789 
Operating margin as % of net sales
- Number of Estimates     17 19 
- Highest     28.6 27.9 27.0 28.2 27.4 29.0 
- Consensus 27.2 26.8 26.7 26.4 25.8 26.2 26.6 27.0 
- Lowest     24.3 25.7 23.9 24.4 25.2 25.8 
Financial income & expense
- Number of Estimates     16 16 
- Highest     -72 -238 -291 -195 -27 184 
- Consensus -97 -390 -100 -380 -372 -327 -269 -200 
- Lowest     -130 -493 -522 -509 -497 -486 
Tax rate in %
- Number of Estimates     14 13 
- Highest     -20.6 -23.5 -24.0 -23.3 -22.3 -21.7 
- Consensus -25.0 -23.0 -24.5 -24.5 -24.8 -24.8 -24.7 -24.7 
- Lowest     -26.7 -26.0 -27.0 -27.0 -27.0 -27.0 
Business net income
- Number of Estimates     17 20 
- Highest     1,764 7,517 7,998 8,531 9,265 10,358 
- Consensus 1,726 7,371 1,687 7,177 7,055 7,586 8,147 8,742 
- Lowest     1,540 6,891 6,407 6,869 7,613 8,032 
Net profit margin as % of net sales
- Number of Estimates     17 19 
- Highest     20.4 20.4 20.6 21.3 21.8 23.2 
- Consensus 19.6 19.9 19.3 19.3 18.9 19.4 19.8 20.3 
- Lowest     17.6 18.7 17.6 18.0 18.9 18.9 
Number of shares
- Number of Estimates     16 15 
- Highest     1,304 1,305 1,294 1,294 1,294 1,294 
- Consensus 1,308 1,306 1,289 1,288 1,255 1,241 1,231 1,221 
- Lowest     1,284 1,274 1,225 1,205 1,187 1,169 
Business EPS (in EUR)
- Number of Estimates     17 24 
- Highest     1.37 5.82 6.32 6.73 7.20 8.07 
- Consensus 1.32 5.64 1.31 5.58 5.64 6.14 6.65 7.21 
- Lowest     1.20 5.34 5.16 5.61 6.27 6.65 
Dividend per Share (in EUR)
- Number of Estimates     16 12 12 12 11 
- Highest     3.05 3.20 3.60 3.90 4.30 
- Consensus 2.93 2.99 3.06 3.26 3.53 3.81 
- Lowest     2.93 2.84 3.03 3.14 3.23 
More estimates on Vara Online Services
Last update 28/04/2016 / This consensus includes the transaction between Sanofi and Boehringer Ingelheim.
The above consensus estimates are reset after each quarterly report. Hence, the estimates do not contain any estimates older than three months.
Disclaimer
This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.